Is Verastem, Inc. (2VSA.F) a Buy, Sell, or Hold?
FSX : 2VSA.F
Verastem, Inc.
$5.238 EUR
$0.26 (5.22%)
- Volume
- 15
- Average Volume
- 493
- Market Capitalization
- $363.07M
- P/E Ratio
- -2.42
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $9.00
- Year Low
- $2.88
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.04
Company Overview
FSX
Daniel W. Paterson
Biotechnology
Healthcare
2VSA.F
102
US
EUR
Liquidity Metrics
1.05
3.04
3.00
2.48
0.00
Sales & Valuation
$30.92M
8.46
7.27
-2.75
-1.55
Profitability
-$3.02
-$209.49M
-391.16%
-391.16%
-486.41%
-85.14%
P/E Metrics
-2.42
-0.12
-0.12
Analyst Price Target & Rating
1/5
10 Analysts
%
Financial Health Scores
-7.86
3/9
$135.54M
$226.95M
$145.48M
-$210.44M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Michelle Detwiler | Co-Founder |
| Daniel Calkins | Chief Financial Officer |
| Lori Horvat | Executive Vice President of Portfolio Strategy & Operations |
| Michael Glen Kauffman | President of Development & Director |
| Robert A. Weinberg | Co-Founder & Chair of Scientific Advisory Board |
| Mark J. Wanda | Senior VP of Legal & Chief Compliance Officer |
| Jonathan Pachter | Chief Scientific Officer |
| Daniel W. Paterson | President, Chief Executive Officer & Director |
| Cathy Carew | Chief Organizational Effectiveness Officer |
| Julissa Viana | Vice President of Corporate Communications & Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About Verastem, Inc. (FSX:2VSA.F) Stock
Verastem, Inc. is a biopharmaceutical firm in its development phase, concentrating on the advancement and market introduction of therapeutic agents for oncological conditions. A primary investigational compound is VS-6766 (also known as avutometinib). This agent functions as a RAF/MEK clamp, impeding MEK kinase activity and the capacity of RAF to phosphorylate MEK. Its pipeline includes RAMP 201, an adaptive, two-part, multicenter, parallel cohort, randomized, open-label clinical trial. This study assesses the effectiveness and safety of avutometinib, both as a standalone treatment and in conjunction with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK), for individuals with recurrent low-grade serous ovarian cancer. Furthermore, RAMP 202 is a Phase 2 investigati ... on exploring the safety of VS-6766 when co-administered with defactinib in patients diagnosed with KRAS and BRAF mutant non-small cell lung cancer, particularly after they have undergone platinum-based therapy and immune checkpoint inhibition. The company holds significant licensing agreements: one with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and production of products containing avutometinib, and another with Pfizer Inc. granting rights to research, develop, manufacture, and commercialize therapeutic, diagnostic, and prophylactic human applications utilizing Pfizer's FAK inhibitors. Verastem has also forged strategic collaborations. A clinical partnership with Amgen, Inc. involves the RAMP 203 Phase 1/2 trial, which is evaluating avutometinib in combination with Amgen's KRAS-G12C inhibitor, LUMAKRASTM. Additionally, a discovery and development partnership with GenFleet Therapeutics is focused on advancing novel programs aimed at cancers driven by the RAS pathway. Verastem, Inc., founded in 2010, has its corporate headquarters situated in Needham, Massachusetts.
Frequently Asked Questions
-
What is the current Verastem, Inc. (2VSA.F) stock price?
-
Verastem, Inc.(FSX:2VSA.F) stock price is $5.238 in the last trading session. During the trading session, 2VSA.F stock reached the peak price of $9 while $2.88 was the lowest point it dropped to. The percentage change in 2VSA.F stock occurred in the recent session was 5.22% while the dollar amount for the price change in 2VSA.F stock was $0.26.
-
2VSA.F's industry and sector of operation?
-
The FSX listed 2VSA.F is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 2VSA.F?
-
Michelle Detwiler | Co-Founder
Daniel Calkins | Chief Financial Officer
Lori Horvat | Executive Vice President of Portfolio Strategy & Operations
Michael Glen Kauffman | President of Development & Director
Robert A. Weinberg | Co-Founder & Chair of Scientific Advisory Board -
How many employees does 2VSA.F have?
-
Number of 2VSA.F employees currently stands at 102. 2VSA.F operates from 117 Kendrick Street, Needham, MA 02494, US.
-
Link for 2VSA.F official website?
-
Official Website of 2VSA.F is: https://www.verastem.com
-
How do I contact 2VSA.F?
-
2VSA.F could be contacted at phone #781 292 4200 and can also be accessed through its website. 2VSA.F operates from 117 Kendrick Street, Needham, MA 02494, US.
-
How many shares of 2VSA.F are traded daily?
-
The average number of 2VSA.F shares traded daily for last 3 months was 493.
-
What is the market cap of 2VSA.F currently?
-
The market value of 2VSA.F currently stands at $363.07M with its latest stock price at $5.238